The future of immunotherapy in multiple myeloma
Hearn Cho et al.
Long-term follow-up results of the ZUMA-1 trial of anti-CD19 CAR T-cells for non-Hodgkin lymphoma
MPN Advances Day 2017: latest updates in the field
Overcoming the limits: bringing CAR T-cell therapy to the masses
New endpoints in clinical trials to better serve patients
Elihu H. Estey